Peer-reviewed veterinary case report
Serum cystatin C levels in cats with hyperthyroidism and kidney
By Williams, T L et al.·Published in Journal of veterinary internal medicine·2016·Department of Veterinary Medicine, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum Cystatin C Concentrations in Cats with Hyperthyroidism and Chronic Kidney Disease.
- Species:
- cat
Plain-English summary
A group of cats with hyperthyroidism were studied to see if a blood test called serum cystatin C (sCysC) could help predict kidney problems after treatment. The researchers found that sCysC levels did not differ significantly between cats that developed kidney issues and those that did not after their hyperthyroidism was treated. Additionally, sCysC levels did not change much after treatment, suggesting that this test may not be a reliable way to assess kidney function in hyperthyroid cats. Pet owners should discuss other options with their veterinarian for monitoring kidney health in these cases.
People also search for: cat hyperthyroidism kidney problems · serum cystatin C test in cats · cat kidney disease treatment options
Abstract
BACKGROUND: Currently, no test can accurately predict the development of azotemia after treatment of hyperthyroidism. Serum cystatin C concentrations (sCysC) might be less influenced by changes in body muscle mass and so better indicate the presence of concurrent chronic kidney disease (CKD) in hyperthyroidism. HYPOTHESES: sCysC will be higher in hyperthyroid cats that develop azotemia compared with hyperthyroid cats that remain nonazotemic after treatment; sCysC will be higher in nonhyperthyroid cats with azotemic CKD than healthy older cats and, sCysC will decrease after treatment of hyperthyroidism. ANIMALS: Ninety-one cats treated in first opinion practice. METHODS: Case-control study. sCysC were compared between hyperthyroid cats which developed azotemia within 4 months of successful treatment of hyperthyroidism (pre-azotemic group) and hyperthyroid cats which remained nonazotemic after treatment (nonazotemic group), and between nonhyperthyroid cats with azotemic CKD and healthy older cats. sCysC were also compared between hyperthyroid cats before treatment and at time of establishment of euthyroidism. Data are presented as median [25th, 75th percentile]. RESULTS: Baseline sCysC were not different between the pre-azotemic and nonazotemic groups (1.9 [1.4, 2.3] mg/L versus 1.5 [1.1, 2.2] mg/L, respectively; P = .22). sCysC in nonhyperthyroid cats with azotemic CKD and healthy older cats were not significantly different (1.5 [1.0, 1.9] mg/L versus 1.2 [0.8, 1.4] mg/L, respectively; P = .16). sCysC did not change significantly after treatment of hyperthyroidism (pretreatment 1.8 [1.2, 2.3] mg/L, after treatment 1.6 [1.1, 2.4] mg/L; P = .82). CONCLUSIONS AND CLINICAL IMPORTANCE: sCysC do not appear to be a reliable marker of renal function in hyperthyroid cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27155206/